[1]王草叶,贾中芝,王维平.钇-90微球放射性肝段切除——钇- 90微球放射栓塞系列回顾（九）[J].介入放射学杂志,2018,27(12):1210-1216.
　Yttrium - 90 microsphere radiative segmental hepatectomy. A series review of radioembolization with yttrium- 90 microspheres（part Ⅸ）[J].journal interventional radiology,2018,27(12):1210-1216.
点击复制

钇-90微球放射性肝段切除——钇- 90微球放射栓塞系列回顾（九）()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
27
期数:
2018年12期
页码:
1210-1216
栏目:
综述
出版日期:
2018-12-25

文章信息/Info

Title:
Yttrium - 90 microsphere radiative segmental hepatectomy. A series review of radioembolization with yttrium- 90 microspheres（part Ⅸ）
作者:
王草叶;  贾中芝;  王维平
关键词:
【关键词】 肝癌;  钇-90;  放射性肝段切除
文献标志码:
A
摘要:
【摘要】 钇-90（90Y）微球放射性肝段切除（radiation segmentectomy）的概念是由美国西北大学肝癌协作小组在放射性肝叶切除（radiation lobectomy）的基础上，于2011年首先提出。将90Y微球灌注的范围限制在2个肝段以内，在总的剂量不变或增加的情况下对肝脏恶性肿瘤进行高度选择性治疗。这种局部高剂量的方法在提高肿瘤对治疗反应的同时，明显降低了临床的并发症与不良反应。在影像学上，接受90Y微球灌注组织的解剖肝段发生萎缩；同时，对侧肝叶发生不同程度的增生。这一新的治疗概念被称为放射性肝段切除并受到了医学界的广泛关注。现将90Y放射性微球进行肝段切除的方法进行详细介绍，同时对现有文献所报道的临床结果进行总结和评价。

参考文献/References:

［1］ Cheng JC， Wu JK， Lee PC， et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation- induced liver disease［J］. Int J Radiat Oncol Biol Phys， 2004， 60： 1502- 1509.
［2］ Fukumitsu N， Sugahara S， Nakayama H， et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma［J］. Int J Radiat Oncol Biol Phys， 2009， 74： 831- 836.
［3］ Emami B， Lyman J， Brown A， et al. Tolerance of normal tissue to therapeutic irradiation［J］. Int J Radiat Oncol Biol Phys， 1991， 21： 109- 122.
［4］ Dawson LA， Ten Haken RK. Partial volume tolerance of the liver to radiation［J］. Semin Radiat Oncol， 2005， 15： 279- 283.
［5］ Garin E， Lenoir L， Rolland Y， et al. Dosimetry based on 99mTc macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y- loaded glass microspheres： preliminary results［J］. J Nucl Med， 2012， 53： 255- 263.
［6］ Strasberg SM. Nomenclature of hepatic anatomy and resections： a review of the Brisbane 2000 system［J］. J Hepatobiliary Pancreat Surg， 2005， 12： 351- 355.
［7］ Michels NA. Newer anatomy of the liver and its variant blood supply and collateral circulation［J］. Am J Surg， 1966， 112： 337- 347.
［8］ 贾中芝， 赵 添， 王斯妮， 等． 钇- 90 微球治疗肝脏恶性肿瘤的术前肝血管评估——钇- 90微球放射栓塞系列回顾（三）［J］． 介入放射学杂志， 2017， 26： 1151- 1159．
［9］ Bishay V， Biederman D， Tabori N， et al. Impact of vessel identification and guidance software on fluoroscopy time during planning angiography prior to 90yttrium radioembolization segmentectomy［J］. J Vasc Interv Radiol， 2016， 27： S64
［10］ O’Connor PJ， Rothenberg E， van der Bom M， et al. Prediction of segmental response using planning cone- beam CT angiography for yttrium- 90 segmentectomy［J］. J Vasc Interv Radiol， 2017： 28： S213.
［11］ 贾中芝， 谢双双， 郑丽丽， 等． 钇- 90微球的剂量计算——钇- 90微球放射栓塞系列回顾（四）［J］． 介入放射学杂志， 2018， 27： 91- 95．
［12］ Dezarn WA， Cessna JT， DeWerd LA， et al. Recommendations of the American Association of Physicists in Medicine on dosimetry， imaging， and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies［J］. Med Phys， 2011， 38： 4824- 4845.
［13］ Riaz A， Gates VL， Atassi B， et al. Radiation segmentectomy： a novel approach to increase safety and efficacy of radioemboli- zation［J］. Int J Radiat Oncol Biol Phys， 2011， 79： 163- 171.
［14］ Grady ED， Auda SP， Cheek WV. Vasoconstrictors to improve localization of radioactive microspheres in the treatment of liver cancer［J］. J Med Assoc Ga， 1981， 70： 791- 795.
［15］ Salem R， Thurston KG. Radioembolization with 90yttrium microspheres： a state- of- the- art brachytherapy treatment for primary and secondary liver malignancies. Part 1： technical and methodologic considerations［J］. J Vasc Interv Radiol， 2006， 17： 1251- 1278.
［16］ 贾中芝， 赵 添， 王斯妮， 等． 钇- 90微球放射栓塞治疗肝脏恶性肿瘤患者的术前评估与术后随访——钇- 90 微球放射栓塞系列回顾（二）［J］． 介入放射学杂志， 2017， 26： 1057- 1062．
［17］ Bruix J， Sherman M， Llovet JM， et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. European Association for the Study of the Liver［J］. J Hepatol， 2001， 35： 421- 430.
［18］ Palmer MK. WHO handbook for reporting results of cancer treatment［J］. WHO， 1979， 38： 484- 485
［19］ European Association for the Study of the Liver， European Organisation for Research and Treatment of Cancer. EASL- EORTC clinical practice guidelines： management of hepatocellular carcinoma［J］. J Hepatol， 2012， 56： 908- 943.
［20］ Jung ES， Kim JH， Yoon EL， et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization［J］. J Hepatol， 2013， 58： 1181- 1187.
［21］ Chen AP， Setser A， Anadkat MJ， et al. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0［J］. J Am Acad Dermatol，2012， 67： 1025- 1039.
［22］ 郑丽丽， 贾中芝， 王斯妮， 等． 钇- 90微球放射栓塞治疗肝脏恶性肿瘤的不良反应和并发症——钇- 90微球放射栓塞系列回顾（五）［J］． 介入放射学杂志， 2018， 27： 190- 196．
［23］ Gaba RC， Lewandowski RJ， Kulik LM， et al. Radiation lobectomy： preliminary findings of hepatic volumetric response to lobar yttrium- 90 radioembolization［J］. Ann Surg Oncol， 2009， 16： 1587- 1596.
［24］ Vouche M， Lewandowski RJ， Atassi R， et al. Radiation lobectomy： time- dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection［J］. J Hepatol， 2013， 59： 1029- 1036.
［25］ Young JY， Rhee TK， Atassi B， et al. Radiation dose limits and liver toxicities resulting from multiple yttrium- 90 radioembo- lization treatments for hepatocellular carcinoma［J］. J Vasc Interv Radiol， 2007， 18： 1375- 1382.
［26］ Lau WY， Kennedy AS， Kim YH， et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium- 90 resin microspheres［J］. Int J Radiat Oncol Biol Phys， 2012， 82： 401- 407.
［27］ Vouche M， Habib A， Ward TJ， et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation： multicenter radiology- pathology correlation and survival of radiation segmentectomy［J］. Hepatology， 2014， 60： 192- 201.
［28］ Riaz A， Lewandowski RJ， Kulik LM， et al. Complications following radioembolization with yttrium- 90 microspheres： a comprehensive literature review［J］. J Vasc Interv Radiol， 2009， 20： 1121- 1130.
［29］ Padia SA， Kwan SW， Roudsari B， et al. Superselective yttrium- 90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity［J］. J Vasc Interv Radiol， 2014， 25： 1067- 1073.
［30］ Biederman DM， Titano JJ， Korff RA， et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early- stage hepatocellular carcinoma［J］. J Vasc Interv Radiol， 2018， 29： 30- 37.

相似文献/References:

[1]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].journal interventional radiology,2012,(12):348.
[2]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(12):322.
[3]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(12):968.
[4]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
　AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(12):1010.
[5]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
　DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(12):75.
[6]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(12):78.
[7]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
　HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(12):682.
[8]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
　LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(12):1035.
[9]徐 阳,臧 爽,陈路锋,等.Logistic回归及ROC曲线综合评价血生化指标对肝癌TACE术后发热的预测价值 [J].介入放射学杂志,2013,(06):513.
　XU Yang,ZANG Shuang,CHEN Lu? feng,et al. Combination evaluation of plasma biochemical indexes with Logistic regression and ROC analysis in predicting hyperthermia after transcatheter hepatic arterial chemoembolization for liver cancer[J].journal interventional radiology,2013,(12):513.
[10]彭国文,李晓群. 射频消融及组合方案治疗特殊/高危部位肝癌的中远期疗效[J].介入放射学杂志,2013,(06):525.
　PENG Guo? wen,LI Xiao? qun.. The mid?蛳 to?蛳 long term efficacy of radiofrequency ablation together with combination regimen for the treatment of hepatic carcinomas located at special or high?蛳 risk regions[J].journal interventional radiology,2013,(12):525.

备注/Memo

备注/Memo:
（收稿日期：２０１8-０6-25）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2018-12-20